S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.26 (-1.18%)
MSFT   421.06 (-0.09%)
META   489.86 (-0.81%)
GOOGL   150.75 (-0.08%)
AMZN   181.21 (+0.77%)
TSLA   176.88 (-1.64%)
NVDA   906.99 (+0.50%)
NIO   4.69 (+0.43%)
AMD   180.63 (+0.58%)
BABA   72.25 (+0.92%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   117.63 (-1.27%)
CGC   9.33 (-2.30%)
GE   177.24 (-1.60%)
DIS   123.49 (+2.07%)
AMC   3.81 (-12.21%)
PFE   27.78 (+0.00%)
PYPL   66.53 (-0.06%)
XOM   115.23 (+0.23%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.26 (-1.18%)
MSFT   421.06 (-0.09%)
META   489.86 (-0.81%)
GOOGL   150.75 (-0.08%)
AMZN   181.21 (+0.77%)
TSLA   176.88 (-1.64%)
NVDA   906.99 (+0.50%)
NIO   4.69 (+0.43%)
AMD   180.63 (+0.58%)
BABA   72.25 (+0.92%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   117.63 (-1.27%)
CGC   9.33 (-2.30%)
GE   177.24 (-1.60%)
DIS   123.49 (+2.07%)
AMC   3.81 (-12.21%)
PFE   27.78 (+0.00%)
PYPL   66.53 (-0.06%)
XOM   115.23 (+0.23%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.26 (-1.18%)
MSFT   421.06 (-0.09%)
META   489.86 (-0.81%)
GOOGL   150.75 (-0.08%)
AMZN   181.21 (+0.77%)
TSLA   176.88 (-1.64%)
NVDA   906.99 (+0.50%)
NIO   4.69 (+0.43%)
AMD   180.63 (+0.58%)
BABA   72.25 (+0.92%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   117.63 (-1.27%)
CGC   9.33 (-2.30%)
GE   177.24 (-1.60%)
DIS   123.49 (+2.07%)
AMC   3.81 (-12.21%)
PFE   27.78 (+0.00%)
PYPL   66.53 (-0.06%)
XOM   115.23 (+0.23%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.26 (-1.18%)
MSFT   421.06 (-0.09%)
META   489.86 (-0.81%)
GOOGL   150.75 (-0.08%)
AMZN   181.21 (+0.77%)
TSLA   176.88 (-1.64%)
NVDA   906.99 (+0.50%)
NIO   4.69 (+0.43%)
AMD   180.63 (+0.58%)
BABA   72.25 (+0.92%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   117.63 (-1.27%)
CGC   9.33 (-2.30%)
GE   177.24 (-1.60%)
DIS   123.49 (+2.07%)
AMC   3.81 (-12.21%)
PFE   27.78 (+0.00%)
PYPL   66.53 (-0.06%)
XOM   115.23 (+0.23%)

Insmed (INSM) Stock Price, News & Analysis

$27.13
-0.19 (-0.70%)
(As of 09:57 AM ET)
Today's Range
$27.01
$27.47
50-Day Range
$25.72
$29.51
52-Week Range
$16.25
$32.00
Volume
45,838 shs
Average Volume
1.63 million shs
Market Capitalization
$4.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.10

Insmed MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
65.3% Upside
$45.10 Price Target
Short Interest
Bearish
5.95% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.32
Upright™ Environmental Score
News Sentiment
1.10mentions of Insmed in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$2.91 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.65) to ($3.81) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.90 out of 5 stars

Medical Sector

264th out of 939 stocks

Pharmaceutical Preparations Industry

119th out of 435 stocks

INSM stock logo

About Insmed Stock (NASDAQ:INSM)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

INSM Stock Price History

INSM Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
INSM Apr 2024 25.000 put
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Insmed To Present at Three March Conferences
Insmed Full Year 2023 Earnings: EPS Misses Expectations
Insmed: Q4 Earnings Snapshot
Insmed Posts Wider Loss In Q4 - Quick Facts
What Wall Street expects from Insmed's earnings
See More Headlines
Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INSM
Employees
373
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$45.10
High Stock Price Target
$55.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+65.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-749,570,000.00
Net Margins
-245.59%
Pretax Margin
-244.76%

Debt

Sales & Book Value

Annual Sales
$305.21 million
Book Value
($2.32) per share

Miscellaneous

Free Float
142,107,000
Market Cap
$4.05 billion
Optionable
Optionable
Beta
0.92

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

INSM Stock Analysis - Frequently Asked Questions

Should I buy or sell Insmed stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INSM shares.
View INSM analyst ratings
or view top-rated stocks.

What is Insmed's stock price target for 2024?

10 Wall Street analysts have issued 1 year target prices for Insmed's shares. Their INSM share price targets range from $36.00 to $55.00. On average, they predict the company's stock price to reach $45.10 in the next twelve months. This suggests a possible upside of 65.3% from the stock's current price.
View analysts price targets for INSM
or view top-rated stocks among Wall Street analysts.

How have INSM shares performed in 2024?

Insmed's stock was trading at $30.99 at the beginning of 2024. Since then, INSM stock has decreased by 11.9% and is now trading at $27.29.
View the best growth stocks for 2024 here
.

When is Insmed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our INSM earnings forecast
.

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) released its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($1.13) by $0.15. The biopharmaceutical company had revenue of $83.70 million for the quarter, compared to the consensus estimate of $82.15 million. The firm's revenue was up 41.1% on a year-over-year basis. During the same period last year, the business earned ($1.20) earnings per share.

What guidance has Insmed issued on next quarter's earnings?

Insmed issued an update on its FY 2024 earnings guidance on Saturday, February, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $340.0 million-$360.0 million, compared to the consensus revenue estimate of $359.5 million.

What is Will Lewis' approval rating as Insmed's CEO?

14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

Who are Insmed's major shareholders?

Insmed's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.87%), Vanguard Group Inc. (9.51%), Price T Rowe Associates Inc. MD (7.52%), Palo Alto Investors LP (3.85%), Bellevue Group AG (1.60%) and Norges Bank (1.02%). Insiders that own company stock include David R Brennan, John Drayton Wise, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis.
View institutional ownership trends
.

How do I buy shares of Insmed?

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INSM) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners